Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Institutional

Corrections log — page 2

Every correction the Institute has made, including corrections that did not change a conclusion.

Corrections

58 documents · page 2 of 2

Table 1. Corrections on this page, in date order.

ReferenceDateCorrectionDocumentVersion increment
CEI-CR/01204 Dec 2024Provenance label addedA reconstructed value was not labelled as such and now is.Standard CEI-MS-05Yes
CEI-CR/04501 Dec 2024Terminology correctedTwo terms used interchangeably were separated, following a comment-period submission.Synthesis: Kisspeptin-10 in growth hormone deficiency and…Yes
CEI-CR/05029 Oct 2024Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Trial abstract: SURPASS-5No
CEI-CR/03304 Oct 2024Numerical correctionA number in a table was corrected against its source.Synthesis: Retatrutide in type 2 diabetes mellitus: effect on the…Yes
CEI-CR/01801 Jul 2024Attribution correctionA result was attributed to the wrong trial and has been reattributed.Synthesis: Tirzepatide in obstructive sleep apnoea with obesity…Yes
CEI-CR/01121 Jun 2024Broken cross-referenceAn internal reference pointed at the wrong section and has been repaired.Trial abstract: SURMOUNT-1No
CEI-CR/00610 Jun 2024Numerical correctionA number in a table was corrected against its source.Trial abstract: TA1-SEPSIS-CN-ELDERLYYes
CEI-CR/04431 May 2024Numerical correctionA number in a table was corrected against its source.Trial abstract: STEP-8Yes
CEI-CR/00515 May 2024Typographical correctionA spelling or punctuation error was corrected. No conclusion was affected.Register entry: Dr Beatrix Nakamura-SteadmanNo
CEI-CR/03429 Apr 2024Typographical correctionA spelling or punctuation error was corrected. No conclusion was affected.Monograph: CagriSema (cagrilintide with semaglutide)No
CEI-CR/02228 Apr 2024Broken cross-referenceAn internal reference pointed at the wrong section and has been repaired.Draft monograph: Semaglutide, oralNo
CEI-CR/01901 Mar 2024Broken cross-referenceAn internal reference pointed at the wrong section and has been repaired.Monograph: SemaxNo
CEI-CR/02827 Feb 2024Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Draft monograph: CagrilintideNo
CEI-CR/04323 Jan 2024Typographical correctionA spelling or punctuation error was corrected. No conclusion was affected.Synthesis: Thymosin alpha-1 in immune modulation and adjunctive…No
CEI-CR/03116 Jan 2024Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Synthesis: Gonadorelin in growth hormone deficiency and…No
CEI-CR/02922 Dec 2023Provenance label addedA reconstructed value was not labelled as such and now is.Trial abstract: SURPASS-1-RENAL-IMPYes
CEI-CR/05306 Dec 2023Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Trial abstract: AMPLITUDE-O-BODY-COMPNo
CEI-CR/00824 Nov 2023Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Trial abstract: STEPS-RENAL-IMPNo
CEI-CR/02720 Nov 2023Attribution correctionA result was attributed to the wrong trial and has been reattributed.Trial abstract: TB4-PH2-VENOUSULCERYes
CEI-CR/05624 Oct 2023Provenance label addedA reconstructed value was not labelled as such and now is.Defined term: Phase 1Yes
CEI-CR/00708 Oct 2023Attribution correctionA result was attributed to the wrong trial and has been reattributed.Register entry: Dr Miriam Steenkamp-LorenzYes
CEI-CR/03203 Oct 2023Attribution correctionA result was attributed to the wrong trial and has been reattributed.Assessment cycle 2025 Q4Yes
CEI-CR/02005 Sep 2023Provenance label addedA reconstructed value was not labelled as such and now is.Synthesis: Petrelintide in obesity and overweight in adults…Yes
CEI-CR/02527 Aug 2023Typographical correctionA spelling or punctuation error was corrected. No conclusion was affected.Trial abstract: TA1-VACCINE-ELDERLYNo
CEI-CR/04207 Aug 2023Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Monograph: PT-141 (bremelanotide)No
CEI-CR/05405 Aug 2023Attribution correctionA result was attributed to the wrong trial and has been reattributed.Defined term: RandomisationYes
CEI-CR/05519 Jul 2023Broken cross-referenceAn internal reference pointed at the wrong section and has been repaired.Trial abstract: CJC-PH1-ASCENDING-REGIONAL-CNNo
CEI-CR/01702 Jun 2023Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Monograph: NAD+ (nicotinamide adenine dinucleotide)No

page 2 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.